Xphyto Therapeutics Corp (XPHY.CN) WACC Analysis

As of May 23, 2025, Xphyto Therapeutics Corp (XPHY.CN) carries a Weighted Average Cost of Capital (WACC) of 8.6%. WACC reflects the blended rate Xphyto Therapeutics Corp must pay to both equity and debt holders.

Within that, the cost of equity is 7.1%, the cost of debt is 5.0%, and the effective tax rate is 1.8%.

Breakdown of WACC Components

• Long-term bond rate: 3.6% – 4.1%
• Equity market risk premium: 5.5% – 6.5%
• Adjusted beta: 0.65 – 0.95
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.09

What It Means for Investors

With a selected WACC of 8.6%, Xphyto Therapeutics Corp must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects a moderate financing cost structure.